← Back to homeAmgen Drug Added to Immunotherapy Cuts Death Risk 58% in Small Cell Lung Cancer Trial
Patients given Imdelltra with AstraZeneca's Imfinzi lived a median of 21.1 months, versus 12.7 months on Imfinzi alone, in results presented Saturday.
Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources Brief
Adding Amgen's drug Imdelltra to AstraZeneca's immunotherapy Imfinzi lowered patients' risk of dying 58% compared…
More reporting and context continue here.
The complete story is available with Premium.
Read the facts, open questions and supporting sources.
Continue reading with NewsPlain Premium.
Keep reading with NewsPlain Premium
Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.
3 sources behind this story.
By NewsPlain Editorial Team · Published
About this story
We haven’t published a correction to this story.
How NewsPlain works ← Back to home